Invivyd

Invivyd, formerly known as Adagio Therapeutics, is a biopharmaceutical company. Invivyd focuses on discovering, developing, and commercializing antibody-based solutions for infectious diseases with pandemic potential. Invivyd is developing first-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1, and other potential coronaviruses. They believe the antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and long-lasting prophylactic treatments. Their candidates are engineered using industry-leading antibody discovery capabilities, designed to maximize potency and duration of effect.